| Business Summary | | V.I.
Technologies,
Inc.
(VITEX)
develops
biotech
products
designed
to
ensure
a
safer
transfusion
blood
supply.
The
Company's
produces
INACTINE
Pathogen
Inactivation,
a
technology
that
inactivates
blood-borne
pathogens.
The
INACTINE
Pathogen
Inactivation
red
blood
cell
product,
currently
in
a
Phase
II
clinical
trial,
is
designed
to
inactivate
pathogens
contained
in
red
blood
cells,
the
largest
transfusion
market
segment.
Universal
PLA+SD,
currently
in
Phase
III
clinical
trials,
is
the
initial
product
from
VITEX
's
Affinity
Purification
technology
platform.
The
Company
maintains
development
and
commercialization
partnerships
with
Pall
Corporation,
Amersham
Pharmacia
Biotech,
Haemonetics,
Inc.,
the
American
National
Red
Cross
and
Bayer
Corporation.
In
August
2001,
the
Company
divested
its
plasma
operations.
The
plasma
operations
are
responsible
for
producing
intermediate
plasma
fractions
and
virally
inactivated
transfusion
plasma,
PLAS+SD. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VITX
is
a
developer
of
a
broad
portfolio
of
blood
products
and
systems
using
its
proprietary
viral
inactivation
technologies.
For
the
26
weeks
ended
6/30/01,
net
revenues
fell
4%
to
$20.3
million.
Net
loss
totaled
$18.8
million,
up
from
$5.4
million.
Revenues
reflect
lower
sales
from
the
PLAS+/R/SD
business
and
the
absence
of
a
$600
thousand
credit
from
the
Red
Cross
Incentive
Program.
Higher
losses
reflect
increased
spending
on
the
INACTINE/TM/
red
cell
pathogen
inactivation
program. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Samuel Ackerman, M.D., 53 Chairman | $365K | John Barr, 44 Pres,
CEO | 462K | Thomas Higgins, 49 CFO
and Exec. VP of Operations | 285K | Bernadette Alford, Ph.D., 51 Exec.
VP, Regulatory and Clinical Affairs | 117K | Dollar amounts are as of 30-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|